Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has shared an update.
On June 23, 2025, Structure Therapeutics Inc. held its 2025 Annual General Meeting of Shareholders. During the meeting, shareholders elected Eric Dobmeier and Joanne Waldstreicher, M.D. as Class II directors to serve until the 2028 Annual General Meeting. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Furthermore, the compensation of the company’s named executive officers was approved, and it was decided that future advisory votes on executive compensation will be held annually.
The most recent analyst rating on (GPCR) stock is a Buy with a $91.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.
Spark’s Take on GPCR Stock
According to Spark, TipRanks’ AI Analyst, GPCR is a Underperform.
Structure Therapeutics, Inc.’s overall score is largely impacted by its financial performance, reflecting significant financial sustainability risks due to zero revenues and increasing losses, despite strong cash positions. The technical analysis provides a mixed view with some short-term momentum but longer-term concerns. The valuation remains challenging with a negative P/E ratio, indicating a speculative investment reliant on future success in R&D and commercialization.
To see Spark’s full report on GPCR stock, click here.
More about Structure Therapeutics, Inc. Sponsored ADR
Average Trading Volume: 989,849
Technical Sentiment Signal: Sell
Current Market Cap: $1.29B
See more insights into GPCR stock on TipRanks’ Stock Analysis page.